FDA Approves AbbVie's Rinvoq To Treatment Active Ankylosing Spondylitis
30/4 06:27
(RTTNews) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV) Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers....